GIT 27

GIT 27

CAT N°: 16293
Price:

GIT 27 is an orally active, isoxazole compound that exhibits various immunomodulatory properties both in vitro and in preclinical in vivo models of autoimmune diseases by inhibiting inflammatory antigen presentation.{30814} It has been shown to target macrophages, reducing the production of the proinflammatory mediators TNF-?, IL-1?, macrophage migration inhibitory factor, and inducible nitric oxide synthase-mediated nitric oxide generation in both pancreatic islets and peripheral compartments.{30815} GIT 27 can also prevent IL-1?/interferon-?-induced pancreatic islet death in vitro at 10 µg/ml and reduce the cumulative incidence of diabetes and insulitis in a mouse model of type 1 diabetes at 20 mg/kg.{30815}

We also advise you